VYD-2311 is under clinical development by Invivyd and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VYD-2311’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VYD-2311 overview
VYD-2311 is under development for the prevention and treatment of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through intravenous or intramuscular route. It is being developed based on INVYMAB platform.
Invivyd overview
Invivyd, formerly Adagio Therapeutics, is a biopharmaceutical company that discovers, develops and commercializes antibody-based solutions for infectious disease. It is investigating its lead product candidate ADG20, for the treatment and prevention of COVID-19. The company also evaluates ADG10, for use in combination with ADG20 to treat COVID-19; and preventative agents targeting additional coronaviruses, seasonal and pandemic influenza. Its approach focuses on neutralizing antibodies that target conserved epitopes across multiple members of coronavirus family. Invivyd is headquartered in Waltham, Massachusetts, the US.
For a complete picture of VYD-2311’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
